UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000017294
Receipt number R000020068
Scientific Title Laboratory monitoring and the anti-coagulant effect of Fondaparinux after total knee arthroplasty
Date of disclosure of the study information 2015/05/15
Last modified on 2015/04/27 15:36:52

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Laboratory monitoring and the anti-coagulant effect of Fondaparinux after total knee arthroplasty

Acronym

Laboratory monitoring and the anti-coagulant effect of Fondaparinux

Scientific Title

Laboratory monitoring and the anti-coagulant effect of Fondaparinux after total knee arthroplasty

Scientific Title:Acronym

Laboratory monitoring and the anti-coagulant effect of Fondaparinux

Region

Japan


Condition

Condition

The patients who will be performed TKA/THA

Classification by specialty

Orthopedics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the anti-coagulant effect, safety, and the correlation with verious markers of Fondaparinux usage for the patients after TKA/THA.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

incidence of DVT

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Double blind -all involved are blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

6

Purpose of intervention

Prevention

Type of intervention

Medicine

Interventions/Control_1

Fondaparinux usage (1.5mg) for TKA

Interventions/Control_2

Fondaparinux usage (2.5mg) for TKA

Interventions/Control_3

Fondaparinux usage (1.5mg) for THA

Interventions/Control_4

Fondaparinux usage (2.5mg) for THA

Interventions/Control_5

no usage of Fondaparinux usage for TKA

Interventions/Control_6

no usage of Fondaparinux usage for THA

Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

The patients who will be performed TKA/THA

more than 20 years old

Key exclusion criteria

bleeding risks
bleeding tendency
bleeding history
Operation history within 30 days
Renal failure
Liver failure
History of Hypersensitivity reaction for heparin

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Tokifumi Majima

Organization

Hokkaido University, Graduate School of Medicine

Division name

Department of Joint Replacement and Tissue Engineering

Zip code


Address

Kita 15, Nishi 7, Kita-ku, Sapporo

TEL

011-706-5935

Email

tkmajima@med.hokudai.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Tomohiro Onodera

Organization

Hokkaido University Graduate School of Medicine

Division name

Department of Orthopaedic Surgery

Zip code


Address

Kita 15, Nishi 7, Kita-ku, Sapporo

TEL

011-706-5935

Homepage URL


Email

tomozou@med.hokudai.ac.jp


Sponsor or person

Institute

Hokkaido University

Institute

Department

Personal name



Funding Source

Organization

Hokkaido University

Organization

Division

Category of Funding Organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 05 Month 15 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2009 Year 02 Month 10 Day

Date of IRB


Anticipated trial start date

2011 Year 01 Month 31 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 04 Month 27 Day

Last modified on

2015 Year 04 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020068


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name